On Tuesday, Coeur Mining Inc (NYSE:CDE)’s shares declined -6.42% to $5.10.
Coeur Mining Inc (CDE) stated first quarter 2015 revenue of $153.0 million, adjusted EBITDA 1 of $21.7 million, and adjusted net loss 1 of $0.24 per share. Adjusted all-in sustaining costs declined 8% from the fourth quarter of 2014 to $17.66 per silver equivalent ounce 1 , the lowest level in the two years of reporting this metric. Adjusted costs applicable to sales per silver equivalent ounce 1 of $13.71 declined 5% from the fourth quarter.
Coeur Mining, Inc., through its auxiliaries, engages in the ownership, operation, exploration, and development of silver and gold mining properties primarily in the United States, Mexico, Bolivia, Argentina, Australia, Ecuador, Chile, and New Zealand.
Cambrex Corporation (NYSE:CBM)’s shares dropped -6.37% to $35.71.
Cambrex Corporation (CBM) reports results for the first quarter ended March 31, 2015.
Highlights
- Sales raised 18% contrast to the first quarter of 2014, and raised 27% not taking into account foreign currency impact, driven by Innovator products and Controlled Substances.
- EBITDA raised to $18.0 million from $8.4 million in the first quarter of 2014.
- GAAP Diluted EPS from ongoing operations was $0.26 as compared to $0.04 in the first quarter last year and Adjusted Diluted EPS was $0.29 contrast to $0.07 in the same quarter last year.
- Net Cash improved $22.4 million to $7.9 million contrast to Debt, net of cash, of $14.5 million at December 31, 2014.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. The company’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products.
At the end of Tuesday’s trade, TG Therapeutics Inc (NASDAQ:TGTX)‘s shares dipped -6.35% to $13.43.
TG Therapeutics Inc (TGTX) declared its financial results for the first quarter ended March 31, 2015 and recent company developments.
Recent Developments and Forthcoming Events
- Reached a global partnershipto develop and commercialize anti-PD-L1 and anti-GITR antibody research programs in the field of hematologic malignancies
- Presented pre-clinical data on the Company’s IRAK4 compounds at the 2015 American Association for Cancer Research (AACR) Annual Meeting
- Multiple abstracts were accepted for presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois (May 29 - June 2, 2015), counting:
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for b-cell malignancies and autoimmune diseases.
Bloomin’ Brands Inc (NASDAQ:BLMN), ended its Tuesday’s trading session with -6.26% loss, and closed at $21.56.
Bloomin’ Brands Inc (BLMN) stated financial results for the first quarter (“Q1 2015″) ended March 29, 2015 contrast to the first quarter (“Q1 2014″) ended March 30, 2014.
Key highlights for Q1 2015 comprise the following:
Comparable sales for Company-owned U.S. concepts raised 3.6% with traffic enhance of 0.7%
Comparable sales for our Brazilian Outback Steakhouse restaurants raised 6.2%
System-wide development was 14 new restaurants. In March 2015, we opened our first International Carrabba’s Italian Grill in Brazil, known as Abbraccio
Adjusted operating income margin was 9.1% as compared to 8.4% in Q1 2014 and U.S. GAAP operating income margin was 8.1% as compared to 7.8% in the Q1 2014
Bloomin Brands, Inc., through its auxiliaries, owns and operates casual, upscale casual and fine dining restaurants primarily in the United States. The company operates restaurants under various concepts, counting Outback Steakhouse, a casual steakhouse restaurant; Carrabba’s Italian Grill, a casual Italian restaurant; Bonefish Grill, an upscale casual seafood restaurant; and Fleming’s Prime Steakhouse & Wine Bar, a contemporary steakhouse.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
